source
- Roche commits over $1 billion to DualityBio for ADC development targeting TOP1 resistanceRoche's Genentech unit announced a major investment in DualityBio to advance antibody-drug conjugate (ADC) technology. Under the agreement DualityBio will receive an upfront payment of $45 million…
- CAR T therapy moves from cancer to autoimmune disease, leveraging oncology safety lessonsCell therapy that transformed treatment of blood cancers is now being tested for autoimmune disorders, according to a recent opinion piece. Early cancer trials showed high complete response rates…